Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced that on January 2, 2026 its Compensation Committee granted restricted stock unit awards covering an aggregate of 434 shares to three new non-executive employees under the 2024 Inducement Plan.

The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously employees or who return after a bona fide period of non-employment. The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.

News Market Reaction – PRAX

-4.41%

1 alert

-4.41% News Effect

On the day this news was published, PRAX declined 4.41%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU shares granted: 434 shares Employees receiving grants: 3 employees Vesting schedule: 4 annual installments +1 more

4 metrics

RSU shares granted 434 shares Inducement grants to three new non-executive employees on Jan 2, 2026

Employees receiving grants 3 employees New non-executive hires receiving inducement RSUs

Vesting schedule 4 annual installments RSUs vest in four equal annual installments subject to continued employment

Nasdaq rule Rule 5635(c)(4) Inducement grants made in accordance with Nasdaq Listing Rule 5635(c)(4)

Market Reality Check

Price: $318.22 Vol: Volume 786,031 is 1.23x t...

normal vol

$318.22 Last Close

Volume Volume 786,031 is 1.23x the 20-day average of 639,951 shares. normal

Technical Price 294.38 is trading above the 200-day MA at 94.98, reflecting a strong pre-news uptrend.

Peers on Argus

PRAX was up 0.6% while key biotech peers were mixed: AVXL up 4.4%, EYPT, NKTR an...

PRAX was up 0.6% while key biotech peers were mixed: AVXL up 4.4%, EYPT, NKTR and SANA down between 2.4% and 4.76%, and ZBIO roughly flat. This points to stock-specific dynamics rather than a broad sector move.

Historical Context

5 past events · Latest: Jan 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Equity offering priced	Negative	-1.4%	Large underwritten common stock offering with about $575M gross proceeds.
Jan 06	Equity offering proposed	Negative	-1.4%	Company announced proposed common stock and pre-funded warrant offering.
Dec 29	BTD and NDA plans	Positive	+13.3%	FDA Breakthrough Therapy Designation and early 2026 NDA plan for ulixacaltamide.
Dec 11	NDA filing path	Positive	+2.2%	FDA confirmed PRAX may file an NDA for relutrigine in early 2026.
Dec 09	Trial design change	Positive	-4.7%	FDA alignment on simplified single-arm registrational design for elsunersen.

Pattern Detected

PRAX has reacted positively to major regulatory wins and NDA progress, while equity offerings have coincided with modest declines and one pivotal trial design update saw a negative divergence.

Recent Company History

Over the past months, PRAX combined significant clinical and regulatory progress with substantial capital raises. A Breakthrough Therapy Designation and NDA-aligned interactions for ulixacaltamide on Dec 29, 2025 drove a 13.25% gain, while NDA plans for relutrigine on Dec 11 added 2.18%. An FDA-aligned, simplified elsunersen pathway on Dec 9 coincided with a 4.74% drop. October and January underwritten offerings, including a $575M deal on Jan 6, 2026, saw modest -1.45% pressure, highlighting dilution sensitivity.

Market Pulse Summary

This announcement details a small inducement grant of 434 restricted stock units to three new employ...

Analysis

This announcement details a small inducement grant of 434 restricted stock units to three new employees under a 2024 inducement plan, vesting over four years pursuant to Nasdaq Listing Rule 5635(c)(4). Against a backdrop of recent FDA designations, NDA preparations and sizable equity offerings, the grants appear routine for talent retention. Investors following PRAX may focus more on upcoming regulatory milestones, capital allocation, and trial readouts than on this administrative equity award.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), inducement plan, central nervous system (cns), +1 more

5 terms

restricted stock unit financial

"granted restricted stock unit awards covering an aggregate of 434 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under the Praxis Precision Medicines, Inc. 2024 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

central nervous system (cns) medical

"therapies for central nervous system (CNS) disorders characterized by"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

neuronal excitation-inhibition imbalance medical

"CNS disorders characterized by neuronal excitation-inhibition imbalance"

Neuronal excitation-inhibition imbalance occurs when the brain's cells that send signals become too active or not active enough, disrupting normal communication. Imagine a busy city where traffic lights are out of sync, causing traffic jams or empty roads—similar disruptions can affect brain function. For investors, such imbalances can be linked to mental health issues that may influence decision-making, focus, and overall well-being.

AI-generated analysis. Not financial advice.

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on January 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 434 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What did Praxis (PRAX) grant on January 2, 2026 under the 2024 Inducement Plan?

Praxis granted restricted stock unit awards covering an aggregate of 434 shares to three new non-executive employees.

How do the restricted stock units for PRAX vest?

The restricted stock units vest in four equal annual installments, subject to the employee's continued employment on each vesting date.

Why were the PRAX awards granted under Nasdaq Listing Rule 5635(c)(4)?

They were granted as inducements material to the recipients entering employment, which is the purpose allowed under Nasdaq Listing Rule 5635(c)(4).

Who is eligible for awards under the Praxis 2024 Inducement Plan?

The 2024 Inducement Plan is used exclusively for individuals who were not previously employees or who return after a bona fide period of non-employment as inducements to join Praxis.

Does the announcement name executive officers or provide financial guidance for PRAX?

No; the announcement refers to three new non-executive employees and does not provide earnings or guidance figures.